Absorption promoting agent
AssigneeLyfjathroun hf.
InventorsSveinbjorn Gizurarson, Sigridur Olafsdottir, Jakob Lindal Kristinsson, Kolbrun Hrafnkelsdottir, David Rurik Olafsson, Oddur Ingolfsson, Ellen Ruth Ingimundardottir
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising polyoxyethylene glycol, fatty acid mono- and diglyceride ester as an absorption promoting agent and an absorption controlling agent together with a therapeutically, prophylactically and/or diagnostically active substance. The pharmaceutical compositions are especially suitable for mucosal administration such as intranasal administration.
Claims32
A pharmaceutical composition for nasal administration, comprising:
- i) a polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride having the formula (I):
- wherein R1, R2, and R3 are independently selected from the group consisting of C6 to C22 fatty acids, polyoxyethylene glycol (PEG) polymer and hydrogen, provided that it contains at least one C6-C22 fatty acid and at least one PEG polymer;
- ii) a triptan;
- and
- iii) optionally, a physiologically acceptable vehicle.
A pharmaceutical composition for nasal administration, comprising:
- i) a polyoxyethylene glycol-fatty acid mono- or diglyceride having the formula (I):
- wherein R1, R2 and R3 are independently selected from the group consisting of C8 to C10 fatty acids, polyoxvethylene glycol (PEG) polymer and hydrogen, provided that it contains at least one C8-C10 fatty acid and at least one PEG polymer, which is present in 0.01% to 2.5% v/v;
- ii) a triptan;
- iii) water, and present in 0.01% to 2.5% v/v;
- ii) triptan;
- iii) water, and
- iv) optionally a physiologically acceptable vehicle.
A pharmaceutical composition for nasal administration, consisting essentially of:
- i) a polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride having the formula (I):
- wherein R1, R2, and R3 are independently selected from the group consisting of C6 to C22 fatty acids, polyoxyethylene glycol (PEG) polymer and hydrogen, provided that it contains at least one C6-C22 fatty acid and at least one PEG polymer;
- ii) sumatriptan;
- iii) optionally, a physiologically acceptable vehicle;
- and
- iv) optionally one or more components selected from the group consisting of water absorbing polymers, substances which inhibit enzymatic degradation, alcohols, organic solvents, stabilizers, viscosity controlling agents, preservatives, osmotic pressure controlling agents, propellants, air displacement, and mixtures thereof.
A pharmaceutical composition for nasal administration, consisting essentially of:
- i) a polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride having the formula (I):
- wherein R1, R2, and R3 are independently selected from the group consisting of a saturated C8 fatty acid or a saturated C10 fatty acid or a combination thereof, polyoxyethylene glycol (PEG) polymer and hydrogen, provided that it contains at least one saturated C8 fatty acid or saturated C10 fatty acid and at least one PEG polymer;
- ii) a triptan;
- iii) optionally, a physiologically acceptable vehicle;
- and
- iv) optionally one or more components selected from the group consisting of water absorbing polymers, substances which inhibit enzymatic degradation, alcohols, organic solvents, stabilizers, viscosity controlling agents, preservatives, osmotic pressure controlling agents, propellants, air displacement, and mixtures thereof.
Dependencies are inferred from the claim text.